MM is also characterized by augmented expression of programmed cell death ligand 1 (PD-L1), one of the immune checkpoint inhibitory ligands that counterbalance T cell activity by binding to PD-1 on activated T cells (Paiva et al., 2015; Jung et al., 2017). The gene discussed is CD274; the disease is Miyoshi myopathy.